Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia [Yahoo! Finance]
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at UBS Group AG from $188.00 to $178.00. They now have a "buy" rating on the stock.
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? [Yahoo! Finance]
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results [Yahoo! Finance]